Edition:
India

Mallinckrodt Plc (MNK.N)

MNK.N on New York Stock Exchange

2.86USD
22 Oct 2019
Change (% chg)

$0.32 (+12.60%)
Prev Close
$2.54
Open
$2.59
Day's High
$2.86
Day's Low
$2.50
Volume
971,750
Avg. Vol
1,275,978
52-wk High
$32.33
52-wk Low
$1.43

Latest Key Developments (Source: Significant Developments)

Armistice Capital Reports 8.5% Passive Stake In Mallinckrodt As Of Oct. 2
Wednesday, 16 Oct 2019 

Oct 16 (Reuters) - Mallinckrodt Plc ::ARMISTICE CAPITAL, LLC REPORTS A 8.5% PASSIVE STAKE IN MALLINCKRODT PLC AS OF OCT 2 - SEC FILING.  Full Article

Mallinckrodt Announces Positive Top-Line Results From Pivotal Phase 3 Clinical Trial Of Stratagraft Regenerative Tissue In Patients With Deep Partial-Thickness Thermal Burns
Monday, 23 Sep 2019 

Sept 23 (Reuters) - Mallinckrodt Plc ::MALLINCKRODT ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PIVOTAL PHASE 3 CLINICAL TRIAL OF STRATAGRAFT® REGENERATIVE TISSUE IN PATIENTS WITH DEEP PARTIAL-THICKNESS THERMAL BURNS.MALLINCKRODT PLC - STUDY MET BOTH CO-PRIMARY ENDPOINTS WITH HIGH STATISTICAL SIGNIFICANCE.MALLINCKRODT PLC - COMPANY PLANS TO SUBMIT BIOLOGICS LICENSE APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION IN FIRST HALF OF 2020.MALLINCKRODT PLC - STUDY DEMONSTRATED AUTOGRAFT SPARING AND DURABLE WOUND CLOSURE AT THREE MONTHS WITH STRATAGRAFT.  Full Article

Mallinckrodt CEO Sees Pathway To Global Settlement For All Co's Opioid Litigation
Tuesday, 10 Sep 2019 

Sept 10 (Reuters) - Mallinckrodt Plc ::MALLINCKRODT CEO SAYS CO SEES PATHWAY TO GLOBAL SETTLEMENT FOR ALL OPIOID LITIGATION - CONFERENCE.MALLINCKRODT CEO SAYS CO SPENDS ABOUT $40 MILLION A YEAR ON DEALING WITH OPIOID LAWSUITS - CONFERENCE.  Full Article

Mallinckrodt Agrees To Sell Biovectra Inc. To H.I.G. Capital For $250 Million
Tuesday, 10 Sep 2019 

Sept 10 (Reuters) - Mallinckrodt Plc ::PRESS RELEASE - MALLINCKRODT AGREES TO SELL BIOVECTRA INC. TO H.I.G. CAPITAL FOR $250 MILLION.MALLINCKRODT PLC - DEAL FOR FOR APPROXIMATELY $250 MILLION.MALLINCKRODT PLC - NOT ANTICIPATED THAT SALE WILL HAVE ANY MATERIAL TAX IMPACT TO MALLINCKRODT.MALLINCKRODT - DEAL CONSIDERATION INCLUDES FIXED CONSIDERATION OF $175 MILLION, COMPRISED OF AN UPFRONT PAYMENT OF $135 MILLION & LONG-TERM NOTE FOR $40 MILLION.MALLINCKRODT PLC - COMPANY INTENDS TO USE PROCEEDS FROM DIVESTITURE CONSISTENT WITH ITS PREVIOUSLY DISCLOSED CAPITAL ALLOCATION PRIORITIES.MALLINCKRODT PLC - DEAL CONSIDERATION INCLUDES CONTINGENT PAYMENTS OF UP TO $75 MILLION.MALLINCKRODT- TRANSACTION IS ANTICIPATED TO INCLUDE ALL OF BIOVECTRA'S SITES IN PRINCE EDWARD ISLAND, NOVA SCOTIA, CANADA, AS WELL AS ITS EMPLOYEE BASE.  Full Article

Mallinckrodt PLC - Matthew Harbaugh, VP And President, Specialty Generics, Left Co Effective Sept 6
Tuesday, 10 Sep 2019 

Sept 9 (Reuters) - Mallinckrodt Plc ::MALLINCKRODT PLC - MATTHEW HARBAUGH, EXECUTIVE VICE PRESIDENT AND PRESIDENT, SPECIALTY GENERICS, LEFT COMPANY EFFECTIVE SEPTEMBER 6, 2019.  Full Article

Mallinckrodt Reaches Settlement To Resolve "Track 1" Opioid Cases With Ohio Counties Of Cuyahoga & Summit
Friday, 6 Sep 2019 

Sept 6 (Reuters) - Mallinckrodt Plc ::MALLINCKRODT ANNOUNCES SETTLEMENT IN PRINCIPLE TO RESOLVE "TRACK 1" OPIOID CASES WITH THE OHIO COUNTIES OF CUYAHOGA AND SUMMIT.MALLINCKRODT PLC - MALLINCKRODT WILL PAY A TOTAL SUM OF $24 MILLION IN CASH AND DONATE $6 MILLION IN GENERIC PRODUCTS.MALLINCKRODT PLC - DISMISSES ALL NAMED MALLINCKRODT ENTITIES WITH PREJUDICE FROM LAWSUIT.MALLINCKRODT PLC - IF FINALIZED, SETTLEMENT WILL FULLY RESOLVE TRACK 1 CASES AGAINST ALL CO'S ENTITIES CURRENTLY SCHEDULED TO GO TO TRIAL IN OCT IN MDL.MALLINCKRODT PLC - "RESOLVING TRACK 1 CASES GIVES US NECESSARY TIME TO CONTINUE TO WORK TOWARDS A GLOBAL RESOLUTION OF OPIOID LAWSUITS".  Full Article

Mallinckrodt Says Late-Stage Trial Of Kidney Failure Treatment Met Main Goal
Thursday, 15 Aug 2019 

Aug 15 (Reuters) - Mallinckrodt Plc ::MALLINCKRODT ANNOUNCES POSITIVE TOP-LINE RESULTS FROM ITS PIVOTAL PHASE 3 CONFIRM TRIAL OF TERLIPRESSIN IN PATIENTS WITH HEPATORENAL SYNDROME TYPE 1 (HRS-1).MALLINCKRODT PLC - STUDY MET PRIMARY ENDPOINT.MALLINCKRODT - PLANS TO SUBMIT NDA TO FDA IN EARLY 2020.MALLINCKRODT PLC - STUDY MET NEARLY ALL OF PRE-SPECIFIED SECONDARY ENDPOINTS.  Full Article

Mallinckrodt Announces Publication Of Results Of Phase 1B Clinical Trial Of Stratagraft Regenerative Tissue In Burns
Wednesday, 14 Aug 2019 

Aug 13 (Reuters) - Mallinckrodt Plc ::MALLINCKRODT ANNOUNCES PUBLICATION OF RESULTS OF PHASE 1B CLINICAL TRIAL OF STRATAGRAFT® REGENERATIVE TISSUE IN BURNS.MALLINCKRODT - STUDY RESULTS SHOWED THAT STRATAGRAFT-TREATED DEEP PARTIAL-THICKNESS BURNS DID NOT REQUIRE SURGICAL HARVEST OF HEALTHY SKIN BY 28 DAYS.MALLINCKRODT PLC - STRATAGRAFT IS CURRENTLY BEING EVALUATED IN AN ONGOING PIVOTAL PHASE 3 CLINICAL TRIAL.MALLINCKRODT - OBSERVED CHARACTERISTICS OF WOUNDS TREATED WITH STRATAGRAFT WERE COMPARABLE TO THOSE TREATED WITH AUTOGRAFT AT 12 MONTHS AFTER TREATMENT.  Full Article

Mallinckrodt CEO Says Co Is Revisiting Options For Generics Unit, Including Sale
Tuesday, 6 Aug 2019 

Aug 6 (Reuters) - Mallinckrodt Plc ::MALLINCKRODT SAYS EXPECTS ACTHAR RESULTS TO BE WEAKER IN SECOND HALF OF THE YEAR - CONF. CALL.MALLINCKRODT SAYS EXPECTS SPECIALTY GENERICS UNIT TO SEE SUSTAINED GROWTH IN BACK HALF OF THE YEAR- CONF. CALL.MALLINCKRODT SAYS DISCONTINUING DEVELOPMENT OF JAUNDICE DRUG STANNSOPORFIN - CONF. CALL.MALLINCKRODT SAYS DEBT REDUCTION TO BE PRIMARY CAPITAL ALLOCATION PRIORITY IN 2019 - CONF. CALL.MALLINCKRODT CEO SAYS CO IS REVISITING OPTIONS FOR GENERICS UNIT, INCLUDING SALE - CONF. CALL.MALLINCKRODT EXPECTS CLARITY ON OUTCOME OF HEARING IN ITS LAWSUIT AGAINST CENTERS FOR MEDICARE & MEDICAID SERVICES BY END OF AUGUST - CONF. CALL.MALLINCKRODT OPTIMISTIC ABOUT LONG-TERM PROSPECTS FOR ACTHAR BUT SHORT TERM EXPECTS HEADWINDS FROM REIMBURSEMENT - CONF. CALL.MALLINCKRODT SAYS IF JUDGMENT IN LAWSUIT AGAINST CENTERS FOR MEDICARE AND MEDICAID SERVICES GOES AGAINST CO, OTHER LEGAL RECOURSE IS AVAILABLE - CONF. CALL.MALLINCKRODT CEO SAYS, "REGARDLESS OF THE OUTCOME OF CMS (LAWSUIT), WE CERTAINLY CONTINUE TO LOOK AT ACTHAR AS A LONG-TERM INVESTMENT WITH SIGNIFICANT AMOUNTS OF CLINICAL DATA AND NEW PRESENTATIONS COMING OUR WAY." - CONF. CALL.MALLINCKRODT SAYS OUTCOME OF OPIOID CASE IN OKLAHOMA AGAINST OTHER DRUGMAKERS NOT RELEVANT TO CO'S GENERICS BUSINESS - CONF. CALL.MALLINKCRODT CITES MULTIDISTRICT OPIOID LITIGATION CASE IN OHIO AS PARTLY RESPONSIBLE FOR DECISION NOT TO SPIN OFF GENERICS BUSINESS - CONF. CALL.  Full Article

Mallinckrodt PLC Q2 Non-GAAP Earnings Per Share $2.53
Tuesday, 6 Aug 2019 

Aug 6 (Reuters) - Mallinckrodt Plc ::REPORTS STRONG RESULTS IN SECOND QUARTER 2019, RAISES ADJUSTED EPS GUIDANCE FOR 2019, AND ANNOUNCES SUSPENSION OF SPECIALTY GENERICS SPIN-OFF.Q2 ADJUSTED EARNINGS PER SHARE $2.53.Q2 LOSS PER SHARE $0.01 FROM CONTINUING OPERATIONS.Q2 SALES $823.3 MILLION.Q2 EARNINGS PER SHARE $1.92.UPDATED FULL YEAR 2019 GUIDANCE RANGES.SPECIALTY GENERICS SPIN-OFF PLANS SUSPENDED BASED ON CURRENT MARKET CONDITIONS.COMPANY REMAINS COMMITTED TO BECOMING SPECIALTY BRANDS BUSINESS.FY ADJUSTED DILUTED EPS FORECAST RAISED TO $8.40 TO $8.70.PHASE 3 TOPLINE RESULTS FOR STRATAGRAFT REGENERATIVE TISSUE AND TERLIPRESSIN DEVELOPMENT PRODUCTS EXPECTED IN NEXT THREE MONTHS.NOW BELIEVES ACTHAR GEL NET SALES FOR 2019 ARE UNLIKELY TO EXCEED $1 BILLION..SEES 2019 TOTAL NET SALES FOR SPECIALTY BRANDS SEGMENT DOWN 5% TO UP 1%.SEES 2019 TOTAL NET SALES FOR SPECIALTY GENERICS SEGMENT 2% TO 5%.QTRLY NET SALES $823.3 MILLION VERSUS $825.5 MILLION.Q2 REVENUE VIEW $815.9 MILLION -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $8.24 -- REFINITIV IBES DATA.  Full Article

Photo

Johnson & Johnson settles Ohio lawsuits to avoid federal trial

Johnson & Johnson said on Tuesday it will pay $20.4 million to settle claims by two Ohio counties, allowing the U.S. healthcare giant to avoid an upcoming federal trial seeking to hold the industry responsible for the nation's opioid epidemic. | Video